Vinva Investment Management Ltd

Position in EXEL — Exelixis, Inc.

CIK 1968109 SYDNEY, C3

Position in EXEL

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$2,110,359

+$986,865 QoQ

Shares Held

49,204

+92.0% QoQ

Ownership

0.020%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2023

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Vinva Investment Management Ltd holds $66,411,479 across 13 Biotechnology names. EXEL ranks #5 (3.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	INCY	Incyte Corp	300,405	$28,274,118
2	ALNY	Alnylam Pharmaceuticals, Inc.	36,601	$12,110,172
3	REGN	Regeneron Pharmaceuticals, Inc.	14,862	$11,482,975
4	VRTX	Vertex Pharmaceuticals Inc / Ma	9,531	$4,255,972
5	EXEL	Exelixis, Inc. This page	49,204	$2,110,359
6	JAZZ	Jazz Pharmaceuticals plc	11,142	$2,106,395
7	HALO	Halozyme Therapeutics, Inc.	32,126	$2,076,303
8	ASND	Ascendis Pharma A/S	5,694	$1,302,388

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,110,359	49,204	+92.0%	Shares	Sole	2026-05-14
2025-12-31	$1,123,494	25,633	+11.6%	Shares	Sole	2026-02-17
2025-09-30	$948,413	22,964	+57.6%	Shares	Sole	2025-11-13
2025-06-30	$642,333	14,572	-29.1%	Shares	Sole	2025-08-13
2025-03-31	$759,001	20,558	-2.3%	Shares	Sole	2025-05-14
2024-12-31	$700,998	21,051	-10.8%	Shares	Sole	2025-02-11
2024-09-30	$612,082	23,587	-2.1%	Shares	Sole	2024-11-14
2024-06-30	$541,145	24,083	+12.1%	Shares	Sole	2024-08-13
2024-03-31	$509,696	21,479	+222.4%	Shares	Sole	2024-05-13
2023-12-31	$159,821	6,662	—	Shares	Sole	2024-02-13
No filing history on record for this holder in this stock.